We are live on
!
Find out more
FO
FT Options Portfolio holdings
AUM
$66.4M
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter
Est. Return
-1.61%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$116M
AUM Growth
+$21M
(+22%)
Cap. Flow
+$284M
Cap. Flow
% of AUM
244.1%
Top 10 Holdings %
Top 10 Hldgs %
42.12%
Holding
462
New
171
Increased
79
Reduced
68
Closed
122
Top Buys
| 1 |
MDVN
MEDIVATION, INC.
MDVN
|
+$4.59M |
| 2 |
Biogen
BIIB
|
+$3.56M |
| 3 |
Cal-Maine
CALM
|
+$2.79M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$2.48M |
| 5 |
Apple
AAPL
|
+$2.33M |
Top Sells
| 1 |
Baxter International
BAX
|
+$4.11M |
| 2 |
Gilead Sciences
GILD
|
+$2M |
| 3 |
IBM
IBM
|
+$1.48M |
| 4 |
Chipotle Mexican Grill
CMG
|
+$930K |
| 5 |
Expedia Group
EXPE
|
+$914K |
Sector Composition
| 1 | Healthcare | 41.4% |
| 2 | Technology | 6.27% |
| 3 | Consumer Staples | 4.14% |
| 4 | Consumer Discretionary | 2.26% |
| 5 | Materials | 1.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALXN
26
DELISTED
Alexion Pharmaceuticals
ALXN
| $1.01M | 0.87% |
8,673
+5,100
| +143% | +$724K |
|
27
Ligand Pharmaceuticals
LGND
$5.94B
| $1.01M | 0.87% |
13,573
+12,188
| +880% | +$904K |
|
28
PUT
Sarepta Therapeutics
SRPT
$1.82B
| $985K | 0.85% |
95,000
+75,000
| +375% | +$1.39M |
|
|
AGN
29
DELISTED
Allergan plc
AGN
| $933K | 0.8% |
4,038
+2,558
| +173% | +$590K |
|
|
CMRX
30
DELISTED
Chimerix, Inc.
CMRX
| $866K | 0.74% |
220,266
-67,446
| -23% | -$333K |
|
31
CALL
General Mills
GIS
$20.7B
| $839K | 0.72% |
170,900
+36,100
| +27% | +$2.3M |
|
|
ESPR
32
DELISTED
Esperion Therapeutics
ESPR
| $798K | 0.69% |
80,799
+49,503
| +158% | +$820K |
|
33
PUT
Humana
HUM
$46.4B
| $783K | 0.67% |
57,900
+48,500
| +516% | +$8.61M |
|
|
ALXN
34
PUT
DELISTED
Alexion Pharmaceuticals
ALXN
| $756K | 0.65% |
9,000
-8,000
| -47% | -$1.14M |
|
35
Microsoft
MSFT
$2.98T
| $683K | 0.59% |
+13,345
| New | +$693K |
|
36
Five Below
FIVE
$10.9B
| $682K | 0.59% |
+14,695
| New | +$614K |
|
37
CALL
Hershey
HSY
$35.4B
| $679K | 0.58% |
43,100
+6,100
| +16% | +$571K |
|
38
Herbalife
HLF
$1.28B
| $661K | 0.57% |
+22,600
| New | +$676K |
|
|
TYC
39
CALL
DELISTED
TYCO INTL PLC COM SHS (IRL)
TYC
| $622K | 0.53% |
141,149
+42,784
| +43% | +$1.79M |
|
|
EMC
40
DELISTED
EMC CORPORATION
EMC
| $611K | 0.52% |
22,500
| – | – |
|
|
41
PUT
Cal-Maine
CALM
$4.18B
| $610K | 0.52% |
149,500
+6,400
| +4% | +$302K |
|
|
TSRO
42
DELISTED
TESARO, Inc.
TSRO
| $589K | 0.51% |
+7,008
| New | +$312K |
|
|
43
PUT
Apple
AAPL
$4.89T
| $588K | 0.51% |
304,800
+72,800
| +31% | +$1.81M |
|
44
Accenture
ACN
$88.5B
| $578K | 0.5% |
5,100
+2,500
| +96% | +$290K |
|
45
PUT
Invesco CurrencyShares British Pound Sterling Trust
FXB
$77.6M
| $562K | 0.48% |
+60,000
| New | +$8.42M |
|
46
CALL
Clorox
CLX
$11.9B
| $515K | 0.44% |
140,300
+105,400
| +302% | +$13.7M |
|
47
CALL
Ulta Beauty
ULTA
$20.6B
| $504K | 0.43% |
+18,000
| New | +$3.92M |
|
|
LLTC
48
DELISTED
Linear Technology Corp
LLTC
| $501K | 0.43% |
+10,774
| New | +$492K |
|
|
SPLK
49
DELISTED
Splunk Inc
SPLK
| $500K | 0.43% |
+9,227
| New | +$487K |
|
50
CALL
Kimberly-Clark
KMB
$36.2B
| $452K | 0.39% |
134,500
+37,700
| +39% | +$4.93M |
|
Similar funds
MC
FIM
TLIC
MKCM
ACM
MFM
VE
GFWEV
FT Options's Q2 2016 Portfolio in Review
As of Q2 2016, FT Options held 462 positions worth $116M, up 22% from $95.5M the previous quarter. Its ten largest holdings account for 42% of the portfolio.
FT Options deployed $284M of net new capital in Q2 2016, opening 171 new positions and adding to 79 existing holdings. Its largest new stake was Bristol-Myers Squibb: 35,075 shares worth $2.58M.
By sector, the portfolio is most concentrated in Healthcare at 41% of assets, down from 48% a quarter earlier, followed by Technology and Consumer Staples.
On the sell side, the largest reduction was Gilead Sciences, an estimated $2M trimmed.
- FT Options's largest Q2 2016 buy was Bristol-Myers Squibb: 35,075 shares worth $2.58M.
- FT Options added most to MEDIVATION, INC. in Q2 2016, an estimated $4.59M increase.
- FT Options's biggest Q2 2016 reduction was Gilead Sciences, cutting an estimated $2M.
- FT Options fully exited Baxter International in Q2 2016, selling an estimated $4.11M.
- FT Options's ten largest holdings make up 42% of its $116M portfolio in Q2 2016.
- FT Options opened 171 new positions and closed 122 in Q2 2016.
- FT Options's portfolio value rose 22% quarter-over-quarter to $116M.
Based on FT Options's 13F filing for Q2 2016, filed 12 Aug 2016.